Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.59 (
MIP
)
4,906
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Extracellular ATP mediates a diverse array of biological responses in many cell types and tissues, including immune cells. We have demonstrated that ATP induces
purinergic receptor P2X
(7) mediated membrane permeabilization, apoptosis, and cytokine expression in murine mast cells (MCs). Here, we report that MCs deficient in the expression of the P2X(7) receptor are resistant to the ATP-induced membrane permeabilization and apoptosis. However, ATP affects the tyrosine phosphorylation pattern of P2X(7)knockout cells, leading to the activation of ERK1/2. Furthermore, ATP induces expression of several cytokines and chemokines in these cells, including IL-4, IL-6, IFN-gamma, TNF-alpha, RANTES, and
MIP
-2, at the mRNA level. In addition, the release of IL-6 and IL-13 to cell-conditioned medium was confirmed by ELISA. The ligand selectivity and pharmacological profile indicate the involvement of two P2X family receptors, P2X(1) and P2X(3). Thus, depending on genetic background, particular tissue microenvironment, and ATP concentration, MCs can presumably engage different P2X receptor subtypes, which may result in functionally distinct biological responses to extracellular nucleotides. This finding highlights a novel level of complexity in the sophisticated biology of MCs and may facilitate the development of new therapeutic approaches to modulate MC activities.
...
PMID:ATP induces P2X7 receptor-independent cytokine and chemokine expression through P2X1 and P2X3 receptors in murine mast cells. 2135 48
In this study, we investigated the role of extracellular nucleotides in chemokine (KC,
MIP
-2, MCP-1, and CXCL10) expression and secretion by murine primary intestinal epithelial cells (IECs) with a focus on P2Y
6
receptors. qRT-PCR experiments showed that P2Y
6
was the dominant nucleotide receptor expressed in mouse IEC. In addition, the P2Y
6
ligand UDP induced expression and secretion of CXCL10. For the other studies, we took advantage of mice deficient in P2Y
6
(
P2ry6
-/-
). Similar expression levels of P2Y
1
, P2Y
2
,
P2X2
, P2X4, and A
2A
were detected in
P2ry6
-/-
and WT IEC. Agonists of TLR3 (poly(I:C)), TLR4 (LPS), P2Y
1
, and P2Y
2
increased the expression and secretion of CXCL10 more prominently in
P2ry6
-/-
IEC than in WT IEC. CXCL10 expression and secretion induced by poly(I:C) in both
P2ry6
-/-
and WT IEC were inhibited by general P2 antagonists (suramin and Reactive-Blue-2), by apyrase, and by specific antagonists of P2Y
1
, P2Y
2
, P2Y
6
(only in WT), and P2X4. Neither adenosine nor an A
2A
antagonist had an effect on CXCL10 expression and secretion. Macrophage chemotaxis was induced by the supernatant of poly(I:C)-treated IEC which was consistent with the level of CXCL10 secreted. Finally, the non-nucleotide agonist FGF2 induced MMP9 mRNA expression also at a higher level in
P2ry6
-/-
IEC than in WT IEC. In conclusion, extracellular nucleotides regulate CXCL10 expression and secretion by IEC. In the absence of P2Y
6
, these effects are modulated by other P2 receptors also present on IEC. These data suggest that the presence of P2Y
6
regulates chemokine secretion and may also regulate IEC homeostasis.
...
PMID:P2Y
6
Receptors Regulate CXCL10 Expression and Secretion in Mouse Intestinal Epithelial Cells. 2954 Oct 27